Eli Lilly’s extension of its SmartDepot technology evaluation agreement through October 2026, paired with the company’s recent pivot toward oral GLP-1 candidates such as the April-approved Foundayo and a June 2025 licensing deal with Camurus for lipid-based long-acting injectables, has kept trader consensus tilted against a full commercial license by the deadline. The ultrasonic spray-drying sustained-release microsphere platform remains in active preclinical assessment for Lilly’s peptide pipeline, yet competing delivery options and a broader shift away from traditional depot formulations have introduced meaningful uncertainty. With roughly five months remaining, any milestone data release or joint committee update could still shift implied probabilities, but current sentiment reflects the absence of binding commercial terms to date.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডনতুন
নতুন
Oct 7, 2026
নতুন
নতুন
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s extension of its SmartDepot technology evaluation agreement through October 2026, paired with the company’s recent pivot toward oral GLP-1 candidates such as the April-approved Foundayo and a June 2025 licensing deal with Camurus for lipid-based long-acting injectables, has kept trader consensus tilted against a full commercial license by the deadline. The ultrasonic spray-drying sustained-release microsphere platform remains in active preclinical assessment for Lilly’s peptide pipeline, yet competing delivery options and a broader shift away from traditional depot formulations have introduced meaningful uncertainty. With roughly five months remaining, any milestone data release or joint committee update could still shift implied probabilities, but current sentiment reflects the absence of binding commercial terms to date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
মার্কেট ওপেন হয়েছে: May 5, 2026, 8:02 PM ET
ভলিউম
$8,308শেষ তারিখ
Oct 7, 2026মার্কেট ওপেন হয়েছে
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s extension of its SmartDepot technology evaluation agreement through October 2026, paired with the company’s recent pivot toward oral GLP-1 candidates such as the April-approved Foundayo and a June 2025 licensing deal with Camurus for lipid-based long-acting injectables, has kept trader consensus tilted against a full commercial license by the deadline. The ultrasonic spray-drying sustained-release microsphere platform remains in active preclinical assessment for Lilly’s peptide pipeline, yet competing delivery options and a broader shift away from traditional depot formulations have introduced meaningful uncertainty. With roughly five months remaining, any milestone data release or joint committee update could still shift implied probabilities, but current sentiment reflects the absence of binding commercial terms to date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ভলিউম
$8,308শেষ তারিখ
Oct 7, 2026মার্কেট ওপেন হয়েছে
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s extension of its SmartDepot technology evaluation agreement through October 2026, paired with the company’s recent pivot toward oral GLP-1 candidates such as the April-approved Foundayo and a June 2025 licensing deal with Camurus for lipid-based long-acting injectables, has kept trader consensus tilted against a full commercial license by the deadline. The ultrasonic spray-drying sustained-release microsphere platform remains in active preclinical assessment for Lilly’s peptide pipeline, yet competing delivery options and a broader shift away from traditional depot formulations have introduced meaningful uncertainty. With roughly five months remaining, any milestone data release or joint committee update could still shift implied probabilities, but current sentiment reflects the absence of binding commercial terms to date.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা